David B. Perez new President of Gambro BCT

David B. Perez new President of Gambro BCT Stockholm, Sweden, August 21, 2000 - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that David B. Perez, 41, has been appointed new President of Gambro BCT. Daivd B. Perez has 20 years of experience from the healthcare service and products industry in the US. His extensive and successful career includes various leadership and management positions in companies including blood bank services and products, physician practice management and home therapy services. Perez joined Gambro BCT in 1999 as Vice President US Sales and Global Marketing. He has played a key role in helping the company build upon its global leadership position in apheresis technology, expanding into the much larger blood bank technology marketplace around the world. Previously he was Vice President Operations of UroTherapies with responsibility for a national network of physician practices. He has been Vice President Western Operations of Haemonetics with responsibility for sales, operations and service. Perez holds a Bachelors Degree from Texas Tech University. "I am extremely happy to have David Perez appointed President of Gambro BCT. I am sure that he will develop and bring the company further into the future", says Sören Mellstig, President and CEO of Gambro. "He has an extensive experience and knowledge of the medical technology and healthcare industry. He has a proven track record, he is a strong leader, and has a lot of energy and enthusiasm for Gambro BCT and for the blood banking industry. Let me also add that I see it as a sign of the strength of our organization that this recruitment is done internally." Gambro BCT The business area Gambro BCT, with revenues of about USD 165 M, includes two segments, Blood Bank Technology and Therapeutic Specialties. Blood Bank Technology includes products and services that enable blood centers to collect, purify, and store blood components. This includes products for automatic collection, apheresis technology and filters for removal of white blood cells from red blood cells as well as IT applications for blood centers/ blood banks. Therapeutic Specialties includes therapeutic apheresis and stem-cell therapy. Blood Bank Technology accounts for about three-quarters of the business area's sales, with Therapeutic Specialties accounting for the remaining 25%. Gambro BCT has about 1,000 employees. For further information please contact: Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8- 613 65 00, +46-70-513 65 33 Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35, +46-70-513 65 34 Cindy Lyman or Kerry Schneider, Citigate Dewe Rogerson, New York , tel. +1-212-688 6840 ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/08/21/20000821BIT00780/bit0001.doc http://www.bit.se/bitonline/2000/08/21/20000821BIT00780/bit0002.pdf

About Us

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.